Go to Healthcare Professionals website This information is for Patients & Caregivers Menu

THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT RITUXAN: INFUSION REACTIONS, SEVERE SKIN AND MOUTH REACTIONS, HEPATITIS B VIRUS (HBV) REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Prescribing Information

Patient Support

Talk to a Nurse Educator in person.

1-888-455-2220

This is not meant to replace the advice of your healthcare team.

Resources and support

RITUXAN Patient Assistance Programs

RITUXAN Access Solutions®—Connecting patients to RITUXAN
If you are worried about paying for RITUXAN, RITUXAN Access Solutions has programs to help you. We may be able to work with you if:

To contact RITUXAN Access Solutions:

The Genentech BioOncology® Co-pay Card
The Genentech BioOncology Co-pay Card may be able to help with the out-of-pocket costs of your RITUXAN prescription. Some health plans might not accept a co-pay card. Please contact your insurance provider to find out if your plan allows the use of co-pay cards. To find out if you qualify for this program or to get a co-pay card, call (855) MYCOPAY/(855) 692-6729. Click here to find out if you are eligible.

RITUXAN Access Solutions: Commitment to Patient Access
RITUXAN Access Solutions is a program that helps people who are taking RITUXAN. Your insurance coverage and the cost of your medicine might keep you from getting the treatment you need. We might be able to help. To learn more about RITUXAN Access Solutions, call (888) 249-4918 or visit Genentech-Access.com/RITUXAN.

Genentech® Access to Care Foundation (GATCF)
GATCF helps people who have health insurance and those who don't. If you qualify for GATCF, you could receive RITUXAN free of charge. Visit Genentech Access to Care Foundation for more information.

Rituxan is available by prescription only.

INDICATIONS

RITUXAN® (Rituximab) is indicated for the treatment of: 

  • Low-grade or follicular CD20-positive Non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
  • Follicular CD20-positive Non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
  • Low-grade CD20-positive Non-Hodgkin's lymphoma as a single agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy
  • CD20-positive diffuse large B-cell Non-Hodgkin's lymphoma as an initial treatment in combination with CHOP chemotherapy
  • CD20-positive chronic lymphocytic leukemia in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred

People with serious infections should not receive RITUXAN.

It is not known if RITUXAN is safe or effective in children.

Important Safety Information

What is the most important information I should know about RITUXAN? 

Tell your doctor right away about any side effect you experience. RITUXAN can cause serious side effects that can lead to death, including: 

  • Infusion Reactions: may occur during or within 24 hours of your infusion. Your doctor should give you medicines before your treatment. Symptoms can include hives, rash, itching, facial or oral swelling, sudden cough, shortness of breath, difficulty breathing, weakness, dizziness, feeling faint, racing heart, or chest pain 
  • Severe Skin and Mouth Reactions: symptoms can include painful sores, ulcers, or blisters on your skin, lips or mouth; peeling skin; rash; or pustules 
  • Hepatitis B Virus (HBV) Reactivation: may cause serious liver problems including liver failure and death. If you have had hepatitis B or are a carrier of HBV, receiving RITUXAN could cause the virus to become an active infection again. You should not receive RITUXAN if you have active HBV liver disease. Your doctor will do blood tests to check for HBV infection prior to treatment and will monitor you during and for several months following your treatment 
  • Progressive Multifocal Leukoencephalopathy (PML): a rare, serious brain infection that can lead to severe disability and death and for which there is no known prevention, treatment, or cure. Symptoms can include difficulty thinking, loss of balance, changes in speech or walking, weakness on one side of your body, or blurred or lost vision 

What are the additional possible serious side effects of RITUXAN? 

Tell your doctor right away about any side effect you experience. RITUXAN can cause serious side effects that can lead to death, including: 

  • Tumor Lysis Syndrome (TLS): may cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, and can lead to death. Your doctor may give you medicines before your treatment to help prevent TLS 
  • Serious Infections: can happen during and after treatment and can lead to death. These infections may be bacterial, fungal, or viral. Symptoms can include fever; cold or flu symptoms; earache or headache; pain during urination; white patches in the mouth or throat; cuts or scrapes that are red, warm, swollen, or painful 
  • Heart Problems: symptoms can include chest pain and irregular heartbeats that may require treatment. Your doctor may need to stop your treatment 
  • Kidney Problems: your doctor should do blood tests to check how well your kidneys are working 
  • Stomach and Serious Bowel Problems: can include blockage or tears in the bowel that can lead to death. Stomach area pain during treatment can be a symptom 
  • Low Blood Cell Counts: your blood cell counts may be monitored during treatment 

The most common side effects of RITUXAN are infusion reactions, chills, infections, body aches, tiredness, and low white blood cells. 

Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. It is not known if RITUXAN may harm your unborn baby or pass into your breast milk. Women should use birth control while using RITUXAN and for 12 months after treatment.

Tell your doctor about any side effect that bothers you or that does not go away.

These are not all of the possible side effects of RITUXAN. For more information, ask your doctor or pharmacist.

Please see the RITUXAN full Prescribing Information, including the Medication Guide, for additional important safety information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

You may also report side effects to Genentech at (888) 835-2555.

THIS INFORMATION DOES NOT TAKE THE PLACE OF TALKING WITH YOUR DOCTOR. DISCUSS WITH YOUR DOCTOR ANY QUESTIONS YOU HAVE ABOUT YOUR MEDICAL CONDITION OR YOUR TREATMENT.